Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.64 |
| ▸ | FNTA | P49354 | 8/20 | 0.43 |
| ▸ | FNTB | P49356 | 8/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8209031 | 0.85 | TAAR1 (0.61) | TAAR1FNTAFNTBNOTUM | |
| SCHEMBL8203453 | 0.84 | TAAR1 (0.64) | TAAR1FNTAFNTBADRA1ANOTUM | |
| SCHEMBL8205622 | 0.80 | TAAR1 (0.62) | TAAR1FNTAFNTBNOTUM | |
| SCHEMBL12993146 | 0.79 | TAAR1 (0.64) | TAAR1FNTAFNTBADRA2CCYP19A1 | |
| SCHEMBL508524 | 0.78 | TAAR1 (1.00) | TAAR1FNTAFNTBADRA1A | |
| SCHEMBL8203733 | 0.77 | TAAR1 (0.59) | TAAR1FNTAFNTBADRA1AADRA1D | |
| SCHEMBL1734439 | 0.75 | TAAR1 (0.49) | TAAR1FNTAFNTBNOTUM | |
| SCHEMBL3524521 | 0.74 | NOTUM (0.40) | TAAR1NOTUM | |
| SCHEMBL12993245 | 0.74 | TAAR1 (0.67) | TAAR1FNTAFNTBNOTUM | |
| SCHEMBL12993227 | 0.74 | TAAR1 (0.67) | TAAR1FNTAFNTBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| WO-2008058867-A2 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | TAAR1, TAAR5, TACR1 | TAAR1 1/4885FNTA 3660/4885FNTB 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.